Wells Fargo raised the firm’s price target on Tenet Healthcare (THC) to $252 from $238 and keeps an Overweight rating on the shares following quarterly results. Overall, modestly higher EBITDA estimates and rolling fully to 2027 estimates offsets a material increase in the odds of enhanced exchange subsidies expiring in the firm’s price target framework, Wells says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Secures $1.9 Billion Credit Facility
- Tenet Healthcare Announces $2 Billion Debt Refinancing
- Tenet Healthcare price target raised to $240 from $225 at Truist
- Tenet Healthcare price target raised to $235 from $225 at Mizuho
- Tenet Healthcare price target raised to $252 from $230 at RBC Capital